## Core Concept
P-glycoprotein (P-gp) is a transmembrane protein that acts as an efflux pump, playing a significant role in the multidrug resistance of cancer cells and the pharmacokinetics of various drugs. Inhibitors of P-glycoprotein can increase the bioavailability and tissue retention of drugs that are P-gp substrates.

## Why the Correct Answer is Right
The correct answer, , is not provided, but we can infer that it does not inhibit P-glycoprotein. Typically, drugs that inhibit P-glycoprotein are used to overcome multidrug resistance in cancer treatment or to increase the absorption of drugs that are substrates for P-gp. Common P-gp inhibitors include verapamil, cyclosporine, and ritonavir.

## Why Each Wrong Option is Incorrect
- **Option A:** is likely a known inhibitor of P-glycoprotein, which makes it incorrect as the answer to the question about which drug is not an inhibitor.
- **Option B:** could be another inhibitor, similar to verapamil or cyclosporine, which are well-known for their P-gp inhibitory activity.
- **Option C:** might also inhibit P-gp, contributing to its pharmacokinetic profile or its use in combination with other drugs to enhance their efficacy.

## Clinical Pearl / High-Yield Fact
A key point to remember is that P-glycoprotein inhibitors can significantly affect the pharmacokinetics of many drugs, potentially leading to increased drug concentrations and toxicity. For example, when cyclosporine (a P-gp inhibitor) is co-administered with drugs that are P-gp substrates, it can lead to increased levels of those drugs.

## Correct Answer: D.